In a recent press release, Boehringer Ingelheim announced its 230 million euro investment in new development center.
Biberach, Germany, 22 June, 2018 – Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center.
“The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.”
Editors note: this press release originally appeared on Boehringer Ingelheim's website.
To view the full press release, click here.
News from our Partners